Literature DB >> 27003156

Serous tubal intraepithelial carcinoma, chronic fallopian tube injury, and serous carcinoma development.

Karin Malmberg1, Charlotta Klynning2, Angelique Flöter-Rådestad2, Joseph W Carlson3,4.   

Abstract

Ovarian carcinoma is the deadliest gynecological malignancy. Previous studies have suggested that the fallopian tube may be the primary site for high-grade serous carcinoma. In prophylactic salpingo-oophorectomies from women with hereditary high risk for ovarian cancer, precursors can be assessed prior to onset and studied as a model for serous cancer precursor lesions. Epidemiologic studies indicate that carcinogenesis may be a result of chronic fallopian tube injury. The aims of this study were to (1) to examine the incidence of serous tubal intraepithelial carcinoma (STIC) in relation to other clinical parameters and (2) to evaluate whether chronic fallopian tube injury was related to cancer development. This study enrolled 101 women, comprising the following three groups: hereditary (n = 60), sporadic serous cancer (n = 18; endometrial cancers were excluded), and control (n = 23). The cases were histologically examined and clinical risk factors were collected. The histological changes were compared between different patients and correlated to clinical risk factors. STICs were identified primarily on the fallopian tube fimbria. The incidence of STIC was 3 % in the hereditary patients. In sporadic serous cancer cases, 61 % were associated with STIC and tubal carcinoma (p < 0.001). No differences in tubal injury or inflammation were seen when comparing the sporadic serous cancer group and the control group or within the hereditary group. STIC and invasive cancer were seen more often in the older patients than in the younger patients (p = 0.528). This small study, no correlation with chronic tubal injury or inflammation was identified.

Entities:  

Keywords:  Carcinoma in situ; Fallopian tubes; Inflammation; Ovary; Serous cystadenocarcinoma

Mesh:

Year:  2016        PMID: 27003156     DOI: 10.1007/s00428-016-1928-7

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  29 in total

1.  BRCA, the oviduct, and the space and time continuum of pelvic serous carcinogenesis.

Authors:  Christopher P Crum; Frank D McKeon; Wa Xian
Journal:  Int J Gynecol Cancer       Date:  2012-05       Impact factor: 3.437

2.  Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship.

Authors:  David W Kindelberger; Yonghee Lee; Alexander Miron; Michelle S Hirsch; Colleen Feltmate; Fabiola Medeiros; Michael J Callahan; Elizabeth O Garner; Robert W Gordon; Chandler Birch; Ross S Berkowitz; Michael G Muto; Christopher P Crum
Journal:  Am J Surg Pathol       Date:  2007-02       Impact factor: 6.394

3.  Macrophages in human fallopian tube and ovarian epithelial inclusion cysts.

Authors:  M Gaytán; C Morales; C Bellido; J E Sánchez-Criado; F Gaytán
Journal:  J Reprod Immunol       Date:  2006-10-02       Impact factor: 4.054

Review 4.  A pathologist's road map to benign, precancerous, and malignant intraepithelial proliferations in the fallopian tube.

Authors:  Mitra Mehrad; Gang Ning; Eleanor Y Chen; Karishma K Mehra; Christopher Paul Crum
Journal:  Adv Anat Pathol       Date:  2010-09       Impact factor: 3.875

Review 5.  DNA-repair pathway inhibitors for the treatment of ovarian cancer.

Authors:  Igor Martinek; Krishnayan Haldar; Kezia Gaitskell; Andrew Bryant; Shibani Nicum; Sean Kehoe; Jo Morrison
Journal:  Cochrane Database Syst Rev       Date:  2010-06-16

Review 6.  Possible role of ovarian epithelial inflammation in ovarian cancer.

Authors:  R B Ness; C Cottreau
Journal:  J Natl Cancer Inst       Date:  1999-09-01       Impact factor: 13.506

7.  Pelvic inflammatory disease and the risk of epithelial ovarian cancer.

Authors:  H A Risch; G R Howe
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  1995 Jul-Aug       Impact factor: 4.254

8.  Serous carcinogenesis in the fallopian tube: a descriptive classification.

Authors:  Elke Jarboe; Ann Folkins; Marisa R Nucci; David Kindelberger; Ronny Drapkin; Alexander Miron; Yonghee Lee; Christopher P Crum
Journal:  Int J Gynecol Pathol       Date:  2008-01       Impact factor: 2.762

9.  A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutations.

Authors:  Ann K Folkins; Elke A Jarboe; Aasia Saleemuddin; Yonghee Lee; Michael J Callahan; Ronny Drapkin; Judy E Garber; Michael G Muto; Shelley Tworoger; Christopher P Crum
Journal:  Gynecol Oncol       Date:  2008-03-14       Impact factor: 5.482

Review 10.  Lessons from BRCA: the tubal fimbria emerges as an origin for pelvic serous cancer.

Authors:  Christopher P Crum; Ronny Drapkin; David Kindelberger; Fabiola Medeiros; Alexander Miron; Yonghee Lee
Journal:  Clin Med Res       Date:  2007-03
View more
  4 in total

1.  The conceptual advances of carcinogenic sequence model in high-grade serous ovarian cancer.

Authors:  Hiroshi Kobayashi; Kana Iwai; Emiko Niiro; Sachiko Morioka; Yuki Yamada; Kenji Ogawa; Naoki Kawahara
Journal:  Biomed Rep       Date:  2017-07-27

Review 2.  Pathogenesis and heterogeneity of ovarian cancer.

Authors:  Paul T Kroeger; Ronny Drapkin
Journal:  Curr Opin Obstet Gynecol       Date:  2017-02       Impact factor: 1.927

Review 3.  Cell Origins of High-Grade Serous Ovarian Cancer.

Authors:  Jaeyeon Kim; Eun Young Park; Olga Kim; Jeanne M Schilder; Donna M Coffey; Chi-Heum Cho; Robert C Bast
Journal:  Cancers (Basel)       Date:  2018-11-12       Impact factor: 6.639

Review 4.  Recommendations for diagnosing STIC: a systematic review and meta-analysis.

Authors:  Joep M A Bogaerts; Miranda P Steenbeek; Majke H D van Bommel; Johan Bulten; Jeroen A W M van der Laak; Joanne A de Hullu; Michiel Simons
Journal:  Virchows Arch       Date:  2021-12-01       Impact factor: 4.535

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.